Published in Br J Pharmacol on March 21, 2016
Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway. Drug Des Devel Ther (2016) 0.75
Serum uric acid concentration is associated with hypertensive retinopathy in hypertensive chinese adults. BMC Ophthalmol (2017) 0.75
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96
Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol (2015) 5.43
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol (2015) 4.46
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol (2015) 4.28
Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation (2001) 3.14
Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension (2013) 2.82
Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol (2006) 2.28
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest (2006) 2.03
Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation (2011) 1.76
Prognostic significance of small-artery structure in hypertension. Circulation (2003) 1.66
Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem (2004) 1.65
Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res (2013) 1.61
Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension (2004) 1.57
Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol (2011) 1.51
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation (2008) 1.50
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest (2007) 1.45
Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res (2013) 1.35
CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension (2000) 1.27
Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol (2005) 1.24
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev (2010) 1.24
Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation (2004) 1.21
Role of elastin in spontaneously hypertensive rat small mesenteric artery remodelling. J Physiol (2003) 1.20
Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res (2006) 1.17
Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol (2003) 1.17
Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension (2009) 1.14
Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal (2012) 1.12
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension (2003) 1.09
Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther (2008) 1.07
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury. Circulation (2011) 1.01
Vascular remodeling in hypertension: mechanisms and treatment. Hypertension (2011) 1.01
Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats. Antioxid Redox Signal (2011) 1.01
Pulse pressure, arterial stiffness, and end-organ damage. Curr Hypertens Rep (2012) 0.98
Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens (2010) 0.98
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation (2004) 0.97
Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther (2007) 0.97
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension (2009) 0.96
Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol (2001) 0.96
Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation (2012) 0.91
Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension (2012) 0.91
Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol (2012) 0.90
Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol (2008) 0.89
Microvascular COX-2/mPGES-1/EP-4 axis in human abdominal aortic aneurysm. J Lipid Res (2013) 0.87
Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest (2013) 0.86
Prostaglandin E2 receptor subtypes in human blood and vascular cells. Eur J Pharmacol (2012) 0.85
Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension. J Hypertens (2013) 0.84
Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicol Appl Pharmacol (2013) 0.84
Pivotal role of protein kinase Cdelta in angiotensin II-induced endothelial cyclooxygenase-2 expression: a link to vascular inflammation. Arterioscler Thromb Vasc Biol (2011) 0.84
Endothelium-derived contracting factors mediate the Ang II-induced endothelial dysfunction in the rat aorta: preventive effect of red wine polyphenols. Pflugers Arch (2009) 0.84
HuR mediates the synergistic effects of angiotensin II and IL-1β on vascular COX-2 expression and cell migration. Br J Pharmacol (2015) 0.83
p38 MAPK contributes to angiotensin II-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats. J Hypertens (2009) 0.82
Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. Eur Heart J (2011) 0.79
Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc Natl Acad Sci U S A (2014) 0.79